Here, the authors provide primary care providers a foundation for understanding pediatric hyperkinetic movement disorders, including tips on creation of a differential diagnosis, assessment of risk factors, and guidance on management strategies.
Many augmentation agents have been examined regarding efficacy for antipsychotic-induced tardive dyskinesia (TD).The goal of this systematic review and meta-analysis was to examine the efficacy of these agents used in the treatment of TD.
Some antipsychotics used to treat MDD are associated with activating or sedating effects. In this Academic Highlights, 4 experts offer clinical insights into the impact of these effects on treatment adherence, patient functioning, and quality of life.
The majority of reported cases of risperidone-induced tardive dyskinesia occurred within 1 year after starting the neuroleptic. However, sometimes there was no cause-and-effect relationship of risperidone and tardive dyskinesia. The objective in presenting this particular case is to highlight the challenges in detecting risperidone-induced tardive dyskinesia in the medical setting.
Psychogenic movement disorders (PMDs) are common and frequently comorbid with other physical and psychiatric conditions. However, treatment of PMDs has been largely unsuccessful. This report describes a patient initially diagnosed with a PMD, who later received a diagnosis of comorbid OCD.Â Treatment with exposure and response prevention, an evidence-based psychotherapy for OCD, was successful in treating both conditions. Read on to find out more.
Do you know which of your patients are at risk for developing tardive dyskinesia? Watch this Webcast to learn about how to prevent tardive dyskinesia in your patients and new treatment strategies for your patients who have already been diagnosed.
Your patients taking antipsychotics may be at risk for developing tardive dyskinesia. In this Case and Comment activity, follow Martha, a 60-year-old woman being treated with an antipsychotic medication for her treatment-resistant depression.
Baclofen, a French Exception, Seriously Harms Alcohol Use Disorder Patients Without Benefit
To the Editor: Dr Andrade’s analysis of the Bacloville trial in a recent Clinical and Practical Psychopharmacology column, in which he concluded that “individualized treatment with high-dose baclofen (30-300 mg/d) may be a useful second-line approach in heavy drinkers” and that “baclofen may be particularly useful in patients with liver disease,” deserves comment.1
First, Andrade failed to recall that the first pivotal trial of baclofen, ALPADIR (NCT01738282; 320 patients, as with Bacloville), was negative (see Braillon et al2).
Second, Dr Andrade should have warned readers that Bacloville’s results are most questionable, lacking robustness. Although he cited us,3 he overlooked the evidence we provided indicating that the Bacloville article4 was published without acknowledging major changes to the initial protocol, affecting the primary outcome. Coincidentally (although as skeptics, we do not believe in coincidence), the initial statistical team was changed when data were sold to the French pharmaceutical company applying for the marketing authorization in France. As Ronald H. Coase warned, “If you torture the data long enough, it will confess.”